FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

RAHWAY, N.J.--(BUSINESS WIRE) November 1, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news